The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma

SIMPLE SUMMARY: Assessment of BRAF mutation status is mandatory in advanced, previously untreated melanoma patients since it is present in 40–50% of cases and allows treatment with specific inhibitors. The testing is usually performed on the primary tumor or metastatic lesion; however, in some cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobczuk, Paweł, Kozak, Katarzyna, Kopeć, Sylwia, Rogala, Paweł, Świtaj, Tomasz, Koseła-Paterczyk, Hanna, Gos, Aleksandra, Tysarowski, Andrzej, Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833667/
https://www.ncbi.nlm.nih.gov/pubmed/35159044
http://dx.doi.org/10.3390/cancers14030777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833667/
https://www.ncbi.nlm.nih.gov/pubmed/35159044
http://dx.doi.org/10.3390/cancers14030777

Ejemplares similares